Готові списки джерел за темами / Lung and breast

Добірка наукової літератури з теми "Lung and breast"

Автор: Grafiati
Опубліковано: 7 липня 2024
Оновлено: 7 липня 2024

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Lung and breast".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Зміст

  1. Статті в журналах
  2. Дисертації
  3. Книги
  4. Частини книг
  5. Тези доповідей конференцій
  6. Звіти організацій

Статті в журналах з теми "Lung and breast":

1

Law, Maria Y. Y., Fion W. K. Cheung, Vincent W. C. Wu, Venus W. C. Tsang, Rainnie W. Y. Kwan, Johnny Y. T. Cheng, and Fatson K. F. Wong. "An evaluation of three tangential breast irradiation techniques in Hong Kong." Journal of Radiotherapy in Practice 2, no. 1 (March 2000): 9–15. http://dx.doi.org/10.1017/s1460396900000030.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Background and Purpose: Loco-regional radiotherapy after breast conserving surgery significantly reduces the risk of recurrence but may induce complications in the lungs. The complications are related to the lung volume irradiated and the lung dose delivered. The purpose of this study was to evaluate three tangential breast irradiation techniques i.e. conventional technique, gantry tilting technique and half-beam block technique in terms of the percentage of irradiated lung volume and high dose lung volume for patients of different sizes.Materials and Method: Treatment planning of the three tangential breast irradiation techniques was performed using the CT scans of 20 patients with early-stage breast cancer after lumpectomy.Results: When compared with conventional technique, both half beam block technique and gantry tilting technique irradiated a significantly smaller percentage of lung volume and delivered a smaller percentage of high dose (above 30 Gy) volume in the lung. Patients with large breasts had a significantly higher percentage of lung volume irradiated to above 30Gy than those patients with small and medium breasts. The combined effect of tangential separation and technique only produced significant effect on the percentage of total lung volume irradiated but not on the high dose volume.Conclusions: Gantry tilting and half-beam block techniques can reduce a significant amount of lung volume and high dose lung volume. Half-beam block technique is recommended for small and medium breast size while for large breast size, gantry tilting technique is preferred.
2

Kusdjianto, Amanda Yuanita, Samsuri, Andri, Wijayanto Andi, Subiyantoro Agus, and Habibie Adi. "BILATERAL PNEUMOTHORAX IN LUNG METASTASES OF BREAST CARCINOMA: A CASE REPORT." International Journal of Radiology and Imaging 1, no. 01 (June 29, 2022): 18–21. http://dx.doi.org/10.21776/ub.ijri.2022.001.01.4.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Introduction: Bilateral pneumothorax is a rare case which happens in 1.3 to 1.9 percent of all cases of pneumothorax.1 In breast carcinoma patients, it is due to lung metastasis and first selected conservative therapy.2 Lung metastasis can be found in the appearance of pulmonary nodules called cannon-ball metastases in chest X-Ray (CXR).3 Method: Case report based on findings in chest X-Ray. Result: A 42 year-old female came to ER with sudden shortness of breath and pleuritic pain. She was diagnosed with breast carcinoma 3 years prior the ER visit and had undergone mastectomy on breasts and chemotherapy. Physical examination showed bilaterally decreased breath sounds. CXR AP postion showed bilateral pneumothorax and multiple nodules varied in size indicated lung metastases. Chest tubes with water-sealed drainage were inserted in both side of the lungs. CXR after the insertion showed reduction of the volume of pneumothorax in both side of the lungs and cannon-ball metastases in both sides of the lungs. CXR was performed serially until hospital discharge. Discussion: Bilateral pneumothorax which develops in patients who have history of breast carcinoma is considered very rare.It is caused by the metastatic process and treatment.2 CXR can be used to detect the metastasis and its complications such as pneumothorax.4 Conclusion: Bilateral pneumothorax is rarely seen in patients with breast carcinoma. Early detection of lung metastasis and appropriate therapy of tumor can prevent complications such as pneumothorax.Keywords: bilateral pneumothorax; lung metastases; breast carcinoma; chest X-Ray
3

Singh, Jarmanjeet, Hanine Inaty, Sanjay Mukhopadhyay, and Atul C. Mehta. "Chronic Pulmonary Silicone Embolism from Breast Augmentation Is Not a Common Finding in Explanted Lungs." Pulmonary Medicine 2018 (2018): 1–5. http://dx.doi.org/10.1155/2018/2987072.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Objective. Acute pulmonary silicone embolism (APSE) related to subcutaneous silicone injections is a well-known entity. Recently, a few cases of pathologically confirmed chronic pulmonary silicone embolism (CPSE) from breast implants have been reported. The prevalence of CPSE in women with breast augmentation is unknown. This study was done to determine the prevalence of CPSE in female lung transplant recipients with a history of breast augmentation and to determine whether breast augmentation plays a role in chronic lung diseases requiring lung transplantation. Methods. A retrospective chart review was performed to identify female lung transplant recipients with a history of breast augmentation prior to or at the time of lung transplantation. Ten patients meeting these criteria were identified. The pathologic features of the explanted lungs of these patients were reexamined for CPSE by a board-certified pathologist with expertise in lung transplantation and pulmonary embolism. Results. Of 1518 lung transplant recipients at Cleveland Clinic, 578 were females. Of 578 females, 10 (1.73%) had history of breast augmentation. A total of 84 H&E-stained slides from the explanted lungs from 10 cases were examined. No pathologic evidence of chronic silicone embolism was seen in any of the 10 cases. Conclusions. CPSE is not associated with pulmonary disease leading to lung transplantation. Breast augmentation is not a significant contributor to pulmonary disease requiring lung transplantation. Further studies are required to ascertain the prevalence of CPSE in the general breast augmentation populace and to define the relationship between breast augmentation and pulmonary disease.
4

Kuan, Emma Lo, and Steven F. Ziegler. "Thymic stromal lymphopoietin promotes interplay between breast tumor cells, neutrophils and Ly6Chi monocytes to regulate breast tumor progression." Journal of Immunology 196, no. 1_Supplement (May 1, 2016): 72.2. http://dx.doi.org/10.4049/jimmunol.196.supp.72.2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Abstract Various human cancers display a T helper type 2 (Th2)-like inflammation. One possible mechanism suggested in human breast cancers is thymic stromal lymphopoietin (TSLP) secreted by breast tumor cells which can drive Th2 responses via tumor-associated dendritic cells. However, the interactions between TSLP, tumor cells, and other immune cells remain unclear. We found in breast tumor-bearing mice TSLP can also be produced by two pro-tumor myeloid cell populations, neutrophils and Ly6Chi monocytes. This non-tumor derived TSLP is crucial for both primary breast tumor growth and its metastasis to lungs. One important mechanism is myeloid derived TSLP can directly act on tumor cells and promote survival and TSLP production of tumor cells. Mice transplanted with TSLPR deficient breast tumor cells developed smaller primary breast tumors and fewer lung metastases. Conversely, mice that constitutively express TSLP in lungs transplanted with breast tumor cells had markedly increased lung metastases. Blocking TSLP in lungs resulted in a reduction in the number of lung metastases. We further discovered that TSLP signaling in Ly6Chi monocytes is crucial for their suppressor functions and their ability to differentiate into macrophages in tumors. Transfer of TSLP receptor deficient Ly6Chi monocytes significantly reduced lung metastases in tumor-bearing mice by changing T cell populations in lungs and in tumors. Our work is the first to show myeloid cell derived TSLP plays an important role in promoting breast tumor progression via maintaining tumor cell survival. We also provide a novel mechanism of the requirement of TSLP signaling in differentiation and suppressor functions in Ly6Chi monocytes.
5

Luo, Yu, Lihan Huang, Qiao Lan, Yurui Wu, Yin Li, Xiaorong Cheng, Kunhai Xiong, and Xiaoyu Wu. "Application of Deep Inspiration Breath Hold Technique in Radiotherapy After Breast- Conserving Surgery for Left Breast Cancer and Its Improvement on Cardiac Dose." Proceedings of Anticancer Research 7, no. 5 (September 25, 2023): 61–65. http://dx.doi.org/10.26689/par.v7i5.5373.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Objective: To analyze the application of deep inspiration breath hold technique in radiotherapy after breast-conserving surgery for left breast cancer and the improvement of cardiac dose. Methods: A total of 45 patients with left breast cancer treated in our hospital after breast-conserving surgery were selected, and the selection time was set from January 2020 to August 2022. All patients received radiotherapy. The right breast, heart, and lung volumes, and dose parameters of the heart, lungs, right breast, and left anterior descending coronary artery were compared under free breathing (FB) and deep inspiration breath hold (DIBH) technical modes. Results: The heart volume of the DIBH group was smaller than that of the FB group, and the left and right lung volumes were significantly larger than those of the FB group. In the DIBH group, the heart dose parameters V5, proper lung dose parameters, and left anterior descending coronary artery dose parameters were found lower than that of the FB group, and the differences were statistically significant (P < 0.05). Conclusion: Compared with FB, the DIBH technique can reduce the heart’s size and increase the lung volume when used for radiotherapy after breast-conserving surgery for left breast cancer. It also reduces the dose to the heart, right lung, and left anterior descending coronary artery, thus protecting the heart and lungs.
6

Yang, Yang, Weihai Zhuo, Yiyang Zhao, Tianwu Xie, Chuyan Wang, and Haikuan Liu. "Estimating Specific Patient Organ Dose for Chest CT Examinations with Monte Carlo Method." Applied Sciences 11, no. 19 (September 26, 2021): 8961. http://dx.doi.org/10.3390/app11198961.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Purpose: The purpose of this study was to preliminarily estimate patient-specific organ doses in chest CT examinations for Chinese adults, and to investigate the effect of patient size on organ doses. Methods: By considering the body-size and body-build effects on the organ doses and taking the mid-chest water equivalent diameter (WED) as a body-size indicator, the chest scan images of 18 Chinese adults were acquired on a multi-detector CT to generate the regional voxel models. For each patient, the lungs, heart, and breasts (glandular breast tissues for both breasts) were segmented, and other organs were semi-automated segmented based on their HU values. The CT scanner and patient models simulated by MCNPX 2.4.0 software (Los Alamos National LaboratoryLos Alamos, USA) were used to calculate lung, breast, and heart doses. CTDIvol values were used to normalize simulated organ doses, and the exponential estimation model between the normalized organ dose and WED was investigated. Results: Among the 18 patients in this study, the simulated doses of lung, heart, and breast were 18.15 ± 2.69 mGy, 18.68 ± 2.87 mGy, and 16.11 ± 3.08 mGy, respectively. Larger patients received higher organ doses than smaller ones due to the higher tube current used. The ratios of lung, heart, and breast doses to the CTDIvol were 1.48 ± 0.22, 1.54 ± 0.20, and 1.41 ± 0.13, respectively. The normalized organ doses of all the three organs decreased with the increase in WED, and the normalized doses decreased more obviously in the lung and the heart than that in the breasts. Conclusions: The output of CT scanner under ATCM is positively related to the attenuation of patients, larger-size patients receive higher organ doses. The organ dose normalized by CTDIvol was negatively correlated with patient size. The organ doses could be estimated by using the indicated CTDIvol combined with the estimated WED.
7

Al-Maghrabi, Jaudah A., Elshami M. Elamin, and Hossam A. Abdel-Rahman. "Breast and Axillary Lymph Node Metastases from Advanced Non-small Cell Lung Carcinoma." Journal of King Abdulaziz University - Medical Sciences 18, no. 3 (July 1, 2012): 97–105. http://dx.doi.org/10.4197/med.18-3.7.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Lung cancer metastasizing to the breast is rare. Only few published case reports can be found in the literature. Metastatic lung cancer to the breast and its ipsilateral axillary lymph node is extremely unusual. No awareness of any prior case reports of lung cancer with such a presentation is known. Herein, this study reports an unusual case of a middle aged Saudi female with non-small cell lung cancer that has metastasized, not only to the lungs and the breast, but also to the ipsilateral axillary lymph nodes. It is important for the oncologists to be mindful of rare presentations for such a common malignancy as lung cancer.
8

Markovic, Marina, Dalibor Jovanovic, Zeljko Todorovic, Marija Zivkovic, Aleksandar Dagovic, Slobodanka Mitrović, Marina Petrović, and Jelena Nešić. "Primary Small Cell Carcinoma Of Lung With Metachronous Breast Metastasis." Serbian Journal of Experimental and Clinical Research 18, no. 3 (October 26, 2017): 263–67. http://dx.doi.org/10.1515/sjecr-2016-0087.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Abstract Breast metastases from an extra-mammary malignancy are rare. Among the lung malignancies that metastasise in the breasts, previous literature has described approximately 30 cases of NSCLC and only a few cases of SCLC. Here, we present a 54-year-old woman with metachronous breast metastasis from pulmonary small cell carcinoma. She presented with a soft tissue mass in the right lung hilum. After bronchoscopy with biopsy, SCLC was verified. Th e patient was given 4 cycles of etoposide and cisplatin followed by radiation therapy. Seven months after the diagnosis of primary lung cancer, the patient palpated a mass in her right breast. Clinical examination and further diagnostics revealed the suspected malignancy, and a radical mastectomy was performed. Immunohistochemical findings suggested metastatic SCLC in the breast. Differentiation between primary and metastatic cancer in the breast is very important for therapeutic planning
9

Khan, Sami U., Ying Xia, David Goodale, Gabriella Schoettle, and Alison L. Allan. "Lung-Derived Selectins Enhance Metastatic Behavior of Triple Negative Breast Cancer Cells." Biomedicines 9, no. 11 (October 30, 2021): 1580. http://dx.doi.org/10.3390/biomedicines9111580.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
The lung is one of the deadliest sites of breast cancer metastasis, particularly for triple negative breast cancer (TNBC). We have previously shown that the lung produces several soluble factors that may enhance the metastatic behavior of TNBC, including E-, L-, and P-selectin. In this paper, we hypothesize that lung-derived selectins promote TNBC metastatic behavior and may serve as a potential therapeutic target. Lungs were isolated from mice and used to generate lung-conditioned media (CM). Lung-derived selectins were immunodepleted and TNBC migration and proliferation were assessed in response to native or selectin-depleted lung-CM. A 3D ex vivo pulmonary metastasis assay (PuMA) was used to assess the metastatic progression of TNBC in the lungs of wild-type versus triple-selectin (ELP-/-) knockout mice. We observed that individual lung-derived selectins enhance in vitro migration (p ≤ 0.05), but not the proliferation of TNBC cells, and that ex vivo metastatic progression is reduced in the lungs of ELP-/- mice compared to wild-type mice (p ≤ 0.05). Treatment with the pan-selectin inhibitor bimosiamose reduced in vitro lung-specific TNBC migration and proliferation (p ≤ 0.05). Taken together, these results suggest that lung-derived selectins may present a potential therapeutic target against TNBC metastasis. Future studies are aimed at elucidating the pro-metastatic mechanisms of lung-derived selectins and developing a lung-directed therapeutic approach.
10

Wang, Jing, Ramon Ocadiz-Ruiz, Matthew Hall, Grace Bushnell, Sophia Orbach, Joseph Decker, Ravi Raghani, et al. "Abstract LB347: A lung-mimicking synthetic metastatic niche reveals N1 neutrophils drive breast cancer metastatic dormancy in the lungs." Cancer Research 83, no. 8_Supplement (April 14, 2023): LB347. http://dx.doi.org/10.1158/1538-7445.am2023-lb347.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Abstract 3D scaffolds mimicking the environment in the primary tumor or metastatic organs can deconstruct complex niche signals and facilitate the study of cancer progression and metastasis. Here, we reported that a subcutaneous 3D scaffold implant acted as a lung-mimicking dormant metastatic niche in mouse models of metastatic breast cancer, recruiting lung-tropic circulating tumor cells yet suppressing their growth through potent in situ antitumor immunity. We compared it with the immunosuppressive lungs developing lethal metastases and the dormant lungs suppressing tumor growth derived from breast cancer models with varying tumor aggressiveness and host immunity. Our data suggested that breast cancer-induced Gr1+CD11b+Ly6G+ granulocytic myeloid cells (neutrophils) infiltrated the scaffold implants and lungs, secreting the same signal to facilitate the metastatic seeding of lung-tropic cancer cells in these two types of niches. However, circulating neutrophils with opposing phenotypes and functions (N1 and N2) were selectively recruited and enriched in the dormant scaffolds/lungs and immunosuppressive lungs, respectively, responding to two distinct groups of chemoattractants. N1 or N2 neutrophils established activated or suppressive immune environments in the metastatic niches, directing different fates of cancer cells. The clinical relevance of these scientific findings was validated by the strong positive correlation of a high N1-to-N2 neutrophil chemoattractant ratio with a low-grade primary tumor, a low metastases incidence, and a better prognosis in breast cancer patients. Overall, our study revealed the multifaceted roles of neutrophils in regulating lung metastasis and underscored the importance of N1 neutrophils in driving breast cancer metastatic dormancy in the lungs, inspiring next-generation immunotherapy. Citation Format: Jing Wang, Ramon Ocadiz-Ruiz, Matthew Hall, Grace Bushnell, Sophia Orbach, Joseph Decker, Ravi Raghani, Yining Zhang, Aaron Morris, Jacqueline Jeruss, Lonnie Shea. A lung-mimicking synthetic metastatic niche reveals N1 neutrophils drive breast cancer metastatic dormancy in the lungs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB347.
Більше джерел
Також вас можуть зацікавити розширені добірки на тему "Lung and breast" для конкретних типів джерел:
Статті в журналах Дисертації Книги

Дисертації з теми "Lung and breast":

1

Cheng, Wing-ming Edward. "Emotional well-being in Chinese lung cancer patients." Click to view the E-thesis via HKUTO, 2004. http://sunzi.lib.hku.hk/hkuto/record/B3197157X.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Gupta, Gaorav. "Breast cancer metastasis to the lungs : from genes to mechanisms /." Access full-text from WCMC :, 2007. http://proquest.umi.com/pqdweb?did=1456287491&sid=10&Fmt=2&clientId=8424&RQT=309&VName=PQD.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Cheng, Wing-ming Edward, and 鄭永明. "Emotional well-being in Chinese lung cancer patients." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2004. http://hub.hku.hk/bib/B3197157X.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Cong, Chunling. "Statistical Analysis and Modeling of Breast Cancer and Lung Cancer." Scholar Commons, 2010. http://scholarcommons.usf.edu/etd/3563.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
The objective of the present study is to investigate various problems associate with breast cancer and lung cancer patients. In this study, we compare the effectiveness of breast cancer treatments using decision tree analysis and come to the conclusion that although certain treatment shows overall effectiveness over the others, physicians or doctors should discretionally give different treatment to breast cancer patients based on their characteristics. Reoccurrence time of breast caner patients who receive different treatments are compared in an overall sense, histology type is also taken into consideration. To further understand the relation between relapse time and other variables, statistical models are applied to identify the attribute variables and predict the relapse time. Of equal importance, the transition between different breast cancer stages are analyzed through Markov Chain which not only gives the transition probability between stages for specific treatment but also provide guidance on breast cancer treatment based on stating information. Sensitivity analysis is conducted on breast cancer doubling time which involves two commonly used assumptions: spherical tumor and exponential growth of tumor and the analysis reveals that variation from those assumptions could cause very different statistical behavior of breast cancer doubling time. In lung cancer study, we investigate the mortality time of lung cancer patients from several different perspectives: gender, cigarettes per day and duration of smoking. Statistical model is also used to predict the mortality time of lung cancer patients.
5

Prochazka, Michaela. "The risk of second primary lung carcinoma in breast cancer patients /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-649-2/.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Hellmold, Heike. "Toxicological and endocrinological aspects of cytochrome P450 in breast and lung /." Stockholm, 1998. http://diss.kib.ki.se/1998/91-628-2787-1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Smith, Sarah Jane. "Cancer in Trent region : incidence, mortality and survival." Thesis, University of Nottingham, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.312199.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Arenas, Lahuerta Enrique Javier. "Identification of novel mechanisms in human breast cancer lung metastasis and chemoresistance." Doctoral thesis, Universitat de Barcelona, 2017. http://hdl.handle.net/10803/404730.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Breast Cancer (BC) is one of the major causes of cancer deaths in women. BC is a heterogeneous disease, and within the heterogeneity of the tumor, Tumor-Initiating Cells (TICs) have been reported as important drivers in tumor initiation and progression. On the basis of these observations, we hypothesized that TICs contribute to BC metastasis, as well to chemoresistance. Through genetic, transcriptomic, molecular and therapeutic analyses of tumor xenografts, BC cell lines, and/or human tumors, in this thesis we first demonstrate that RARRES3, a lung metastatic suppressor gene, prevents adhesion to the lung parenchyma and the initiation of metastatic lesions by enforcing the retention of differentiation features and that this retention is driven by its PLA1/2 catalytic activity. These results indicate that RARRES3 genetic activity blocks both tissue-specific metastasis to the lung and metastatic initiation properties. Next, we dissected functional interplay between stem cell (SC)-like master regulator genes (EVI1 and SOX9) and resistance to mTOR inhibitors, which leads to an aggressive metastatic cancer phenotype. Collectively, the data shown in this thesis depict novel evidence regarding the role of tumor initiation properties in: I) BC progression and metastasis; II) how cancer progression is functionally linked to resistance to mTOR; and III) how resistance to therapy driven by tumor initiation properties may eventually produce an aggressive cancer phenotype.
El cáncer de mama (BC, de sus siglas en inglés) es una de las mayores causas de muerte por cáncer en mujeres. El cáncer de mama es una enfermedad heterogénea, y en la heterogeneidad del tumor, las células iniciadoras tumorales (TICs, del inglés) han sido asociadas como importantes responsables en la iniciación y progresión tumoral. Basándonos en estas observaciones, nuestra hipótesis es si estas células contribuyen en la metástasis y quimioresistancia en el cáncer de mama. A través de análisis genéticos, transcriptómicos, moleculares y terapéuticos en xenoinjertos tumorales, líneas celulares y tumores humanos, en esta tesis hemos revelado en primer lugar que RARRES3, es un gen de supresión metastática en pulmón, que previene la adhesión al parénquima pulmonar y la iniciación de lesiones metastáticas, imponiendo las características de diferenciación, y cuya retención es causada por la actividad catalítica PLA1/2. Estos resultados indican que la actividad genética de RARRES3 bloquea específicamente la metástasis a pulmón y las propiedades de iniciación metastática. Además, hemos descrito una relación entre las los genes con características de autorenovación (EVI1 y SOX9) y resistencia a inhibidores de mTOR, que termina con una fenotipo más agresivo y metastático. Conjuntamente, los datos mostrados en esta tesis demuestras evidencias novedosas relacionadas con las propiedades de iniciación tumoral en distintos contextos: I) progresión y metástasis en el cáncer de mama; II) como la progresión tumoral está funcionalmente relacionada con la resistencia a inhibición de mTOR; y III) como la resistencia a terapia que está desencadenada por estas propiedades de iniciación tumoral pueden al final producir un fenotipo más agresivo y metastático
9

Iliopoulos, Dimitrios. "The role of the WWOX tumor suppressor in breast and lung cancer." Columbus, Ohio : Ohio State University, 2006. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1155142398.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Allaire, Patrick. "Erk12 provides retinoic acid resistance to breast and lung cancer cell lines." Thesis, McGill University, 2003. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=78236.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
RARbeta2 is a tumour suppressor activated by retinoic acid (RA). It controls gene expression by heterodimerizing with RXRs on RA response elements. We hypothesised that Erk1/2 inhibits RARbeta2 transcriptional activity in RARbeta2-expressing and RA-resistant cell lines by phosphorylating RXRalpha. Treatment of RA-resistant, RARbeta2-expressing cell lines (A549 and Hs578t) and a RA sensitive cell line (H157) with PD98059 synergized with RA in inhibiting growth. Cloning an active mutant of MEK1 (MEK1DD) into H157 made these cells around 40% less sensitive to ATRA. EGF-mediated Erk1/2 activation inhibited the ATRA-induced transcription of both a synthetic reporter and an endogenous (RARbeta) gene. In both cases, PD98059 reversed this inhibition. Finally, MEK1DD inhibited to approximately 90% transcription from the reporter gene. These results indicate that Erk1/2 reduces RA-mediated transcription by all RARs, possibly by phosphorylating RXRalpha and that RA may be effective clinically when used in combination with drugs acting upstream of MEK1/2 such as Iressa and Herceptin.
Більше джерел

Книги з теми "Lung and breast":

1

1940-, Hayat M. A., ed. Lung and breast carcinomas. Amsterdam: Elsevier, Academic Press, 2008.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Lange, Vladimir. Be a survivor: Lung cancer treatment guide. 2nd ed. Los Angeles, CA: Lange Productions, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Feldman, Philip S. Fine needle aspiration cytology and its clinical applications: Breast & lung. Chicago: American Society of Clinical Pathologists Press, 1985.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Hayat, M. A. General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma. Dordrecht: Springer Netherlands, 2008.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Horowicz-Mehler, Nathalie Cecilia. Risk for Lung or Liver Metastasis in Women with Metastatic Breast Cancer. [New York, N.Y.?]: [publisher not identified], 2017.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

A, Kaplan George, California. Dept. of Health Services., and California Chronic and Sentinel Diseases Surveillance Program., eds. Cancers of the lung, trachea, bronchus, female breast and uterine cervix: Deaths and hospitalizations, California, 1983-1987. Sacramento, CA: California Dept. of Health Services, Chronic Diseases Branch, California Chronic and Sentinel Diseases Surveillance Program, 1991.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Maguire, Patrick. When cancer hits home: Cancer treatment and prevention options for breast, colon, lung, prostate and other common types. [Hilton Head Island, SC]: Coastal Carolina Publishing, LLC, 2010.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Kennedy-Sheldon, Lisa. A nurse's guide to caring for cancer survivors. Sudbury, Mass: Jones and Bartlett Publishers, 2010.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Kennedy-Sheldon, Lisa. A nurse's guide to caring for cancer survivors. Sudbury, Mass: Jones and Bartlett Publishers, 2010.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Kennedy-Sheldon, Lisa. A nurse's guide to caring for cancer survivors. Sudbury, Mass: Jones and Bartlett Publishers, 2010.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Частини книг з теми "Lung and breast":

1

Howarth, Nigel, and Denis Tack. "Missed Lung Lesions." In Diseases of the Heart and Chest, Including Breast 2011–2014, 76–82. Milano: Springer Milan, 2011. http://dx.doi.org/10.1007/978-88-470-1938-6_12.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Shackcloth, Michael, and Susannah Love. "Role of Surgery in Lung Metastases from Breast Cancer." In Breast Cancer Management for Surgeons, 619–23. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56673-3_53.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Mariani, Giuliano, and Laura Bruselli. "Lung Scintigraphy in Pulmonary Embolism." In Diseases of the Heart and Chest, Including Breast 2011–2014, 211–16. Milano: Springer Milan, 2011. http://dx.doi.org/10.1007/978-88-470-1938-6_31.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Cao, Xiao-lin, and Ping Liang. "Microwave Ablation in Other Tumors (Lung, Breast, and Bone)." In Microwave Ablation Treatment of Solid Tumors, 273–80. Dordrecht: Springer Netherlands, 2014. http://dx.doi.org/10.1007/978-94-017-9315-5_25.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Wang, Xiaoyong, Pangyu Teng, Pechin Lo, Ashley Banola, Grace Kim, Fereidoun Abtin, Jonathan Goldin, and Matthew Brown. "High Throughput Lung and Lobar Segmentation by 2D and 3D CNN on Chest CT with Diffuse Lung Disease." In Image Analysis for Moving Organ, Breast, and Thoracic Images, 202–14. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-00946-5_21.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Vlahos, Ioannis, and Heber MacMahon. "CT Diagnosis and Management of Focal Lung Disease." In Diseases of the Heart and Chest, Including Breast 2011–2014, 13–18. Milano: Springer Milan, 2011. http://dx.doi.org/10.1007/978-88-470-1938-6_2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Onieva Onieva, Jorge, Berta Marti-Fuster, María Pedrero de la Puente, and Raúl San José Estépar. "Diffeomorphic Lung Registration Using Deep CNNs and Reinforced Learning." In Image Analysis for Moving Organ, Breast, and Thoracic Images, 284–94. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-00946-5_28.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Vilar, José S., and Jeremy J. Erasmus. "Current Concepts in Diagnosis and Staging of Lung Cancer." In Diseases of the Heart and Chest, Including Breast 2011–2014, 3–12. Milano: Springer Milan, 2011. http://dx.doi.org/10.1007/978-88-470-1938-6_1.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Desai, Sujal R. "Plain Film and HRCT Diagnosis of Interstitial Lung Disease." In Diseases of the Heart and Chest, Including Breast 2011–2014, 83–86. Milano: Springer Milan, 2011. http://dx.doi.org/10.1007/978-88-470-1938-6_13.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Gozes, Ophir, and Hayit Greenspan. "Lung Structures Enhancement in Chest Radiographs via CT Based FCNN Training." In Image Analysis for Moving Organ, Breast, and Thoracic Images, 147–58. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-00946-5_16.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Lung and breast":

1

Watanabe, Priscila Dias, Ruffo Freitas-Júnior, and Nilceana Maya Aires Freitas. "Influence of surgical clip and oncoplasty on breast, heart, and lung volumes irradiated during boost radiotherapy in breast cancer." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1040.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Objective: The objective of this study was to evaluate the irradiated volumes of the breast, heart, and lung, considering the presence of the surgical clip and the oncoplasty techniques Methodology: This is a retrospective study of women submitted to boost radiotherapy tumor bed after breast conservative surgery between January 2011 and January 2021. Statistical analysis using Student’s t-test (95%CI; p<0.05). It was considered volumes of lung and heart relative to 40% of the prescribed dose in the boost radiation planning (V40 Lung) (V40 Heart) and 100% in the breast and boost volume (V100 Breast) (V100 Boost), which were compared by oncoplastic techniques and surgical clips using the dose-volume histogram in three-dimensional conformal radiotherapy. Results: This study evaluated 183 women. For the entire group, regardless of the oncoplasty, when the patient was clipped, there was a significant difference between the mean boost volumes. In the group of patients without oncoplasty, there was a significant difference between the mean boost volumes: V100 Boost=95.66 cm³ (PD±42) in the presence of 1–2 clips and V100 Boost=90.99 cm³ (PD±34) in the presence of 3 or more clips, when compared with non-clipped: V100 Boost=255.23 cm³ (PD±162) (p<0.001), and the difference in mean breast volumes was also significant, in the presence of 1–2 clips, V100 Breast=233.31 cm³ (PD±122), when compared with non-clipped breast: V100 Breast=368.71 cm³ (PD±232) (p=0.032). There was no statistically significant difference in the mean heart and lung volumes analyzed. Conclusion: The presence of the clip significantly reduced the mean boost volume for the entire group. For those who did not undergo oncoplasty, the presence of the clip made it possible to reduce the mean volume of the breast, when one to two clips were inserted. In those undergoing oncoplasty, the presence of the clip increased the cardiac volume. There was no significant difference in the mean lung volumes.
2

Sztejnberg, Manuel L., and Tatjana Jevremovic. "Advanced Application of BNCT in Advanced Cancers." In 17th International Conference on Nuclear Engineering. ASMEDC, 2009. http://dx.doi.org/10.1115/icone17-75906.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
We present a new concept of one form of radiation binary targeted therapy that may offer hope for the often fatal relapsed and/or metastasized HER2+ cancers. The idea is to deliver boronated (boron-10 isotope) anti-HER2 monoclonal antibodies (mAbs) to the patient to be deposited preferentially into the tumor followed by one session of a low energy neutron irradiation. Based on actual computed tomography data, we present the comprehensive theoretical (numerical) modeling of the new approach in designing the treatment conditions for the boron neutron capture therapy (BNCT) using the MITRII-FCB neutron beam facility. The results show the effectiveness of the proposed treatment option for the advanced breast cancers and the metastasized breast cancers in the lungs of a patient. Our theoretical analysis concludes that with a boron concentration of ∼316 μg/g in tumor and a tumor-to-healthy tissue boron concentration ratio of 35:1, this new BNCT breast cancer treatment can be performed with very low doses to normal tissue and 50 Gy, or higher, doses delivered to the tumor regions. In particular, when applied to the breast cancer treatment, the resulting doses to skin and lung remain under the tolerance dose values. We also went beyond the traditional application of the BNCT and analyzed its applicability in targeting the metastasized breast cancer; using the same theoretical approach we determined the doses delivered into the patient lung with scattered cancer loci.
3

Lemos, Nathalia Oliveira, Fábio Bagnoli, Maria Antonieta Longo Galvão Silva, José Francisco Rinaldi, and Vilmar Marques de Oliveira. "INVASIVE LOBULAR BREAST CANCER METASTATIC TO THE ORBIT: A CASE REPORT." In XXIV Congresso Brasileiro de Mastologia. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s1048.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Invasive lobular carcinoma represents 5%–15% of breast carcinomas, presenting in many cases as multicentric and bilateral tumors with low mammographic detection. The most common breast cancer metastases are the bones, lungs, brain, and liver. However, the disease can also spread to abdominal cavity, ovaries, and skin. The orbit is an infrequent site of tumor metastasis, ranging from 1% to 13% among all orbital tumors, and breast, lung, and prostate are among the most common primary sites. We report the case of a 73-year-old female patient who presented with a palpable mass in the left orbital rim, whose incisional biopsy revealed a pattern compatible with invasive breast carcinoma with lobular characteristics and E-cadherin overexpression, luminal molecular subtype B. She denied breast complaints and palpable nodules, but on clinical examination she showed a tumor in the inferolateral quadrant of the left breast measuring 6 cm and a left axilla with lymph node enlargement suspected of lymph node involvement. Mammography identified suspicious nodulation in this topography, confirmed by ultrasound. The diagnosis made through core biopsy was an invasive breast carcinoma with lobular characteristics, and the immunohistochemical profile showed luminal molecular subtype B. Systemic staging revealed involvement of the retroperitoneum, left ovarian annex, vertebral bodies, pelvis, right femur, and left iliac suspected for secondary involvement. The patient is currently undergoing adjuvant systemic treatment.
4

Lin, J. J., Y. Huang, J. P. Wisnivesky, and K. Sigel. "Assessing Lung Cancer Risk in Breast Cancer Survivors." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3054.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Acharya, Sunil, Chenyu Zhang, Frank L. Lowery, Qingling Zhang, and Dihua Yu. "Abstract 2010: SPHK1 promotes lung metastasis of breast cancer." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-2010.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Reis, Gabriel Baêta Branquinho, Hugo Francisco da Fonseca Neto, Alice Jardim Zaccariotti, Daniel Bispo de Sousa, Silvaleide Ataides Assunção, Thiago Martins de Abreu, Fernando Santos de Azevedo, and Lanúscia Morais de Santana. "INVASIVE DUCTAL CARCINOMA IN A PATIENT WITH LI-FRAUMENI SYNDROME: A CASE REPORT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2105.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Introduction/Objectives: Breast cancer is one of the most common malignancies among women, with 10% resulting from genetic predisposition. Li-Fraumeni syndrome is an autosomal dominant disease that predisposes to multiple primary tumors and is responsible for less than 0.1% of breast cancers, being considered in early-onset tumors. The aim of this report was to describe a fast evolution of three primary tumors in a young patient with Li-Fraumeni syndrome, including ductal breast carcinoma. Case Report: In 2017, a 27-year-old female patient was diagnosed with malignant cancer of the right breast, Luminal HER KI67 70%, clinical stage IV (liver and lung), underwent first-line cancer treatment, maintaining endocrinotherapy and Double Block, with a positive genetic panel test for TP53 mutation, inferring SLF. In 2018, screening colonoscopy showed colon adenocarcinoma, pT53pN1, treated with total colectomy with ileal pouch, followed by suspension of endocrinotherapy and maintenance of Double Block and adjuvant FOLFOX. At the end of chemotherapy, endocrinotherapy was adopted again. Reassessment tests showed partial response in the liver, but the primary nodules were unchanged. Biopsy after thoracoscopy described lung adenocarcinoma, pT3pN2, submitted to adjuvant with Gemzar and Navelbine, followed by Double Block and interruption of endocrinotherapy. It evolved with the appearance of nodules in the right breast, suggestive of progression of breast disease, under treatment with Xeloda, Herceptin, and Perjeta, showing good clinical response. Discussion: Breast cancer in young people increases the possibility of heredity, thus raising the need for investigations of genetic syndromes. Although rare, the identification of FHL brings an important implication for the genetic counseling. Early diagnosis is the best form of management, enabling the preventive screening and intervention of multiple malignancies. Conclusion: Cases of breast cancer in young women should raise a suspected diagnosis of Li-Fraumeni syndrome, which can change the therapeutic and investigation of other cancers at an early stage.
7

Shen, Haifa. "Abstract 5697: Multistage vectored nanotherapeutics of breast cancer lung metastasis." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-5697.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Bui, D., J. Perret, C. Lodge, A. Lowe, G. Bowatte, E. Bircan, A. James, et al. "Associations between breast feeding and lung function in middle age." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.1061.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Burgei, J. W., K. Alsheimer, and B. T. Hehn. "A Rare Case of Neuroendocrine Breast Carcinoma With Lung Metastasis." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2397.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Jha, Medha, and Yasha Hasija. "Bioinformatic Analysis of BRCA for Breast, Ovary and Lung Cancer." In 2023 International Conference on Computational Intelligence and Sustainable Engineering Solutions (CISES). IEEE, 2023. http://dx.doi.org/10.1109/cises58720.2023.10183625.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Lung and breast":

1

Wang, Yan, Wenpeng Song, Sicheng Zhou, Jie Tian, Yingxian Dong, Jue Li, Junke Chang, et al. Increased risk for subsequent primary lung cancer among female hormone-related cancer patients: a meta-analysis based on over four million cases. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2022. http://dx.doi.org/10.37766/inplasy2022.7.0044.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Review question / Objective: To identify the risk of lung cancer in FHRC patients compared to the general population. Condition being studied: The incidence rate of lung cancer in women is obviously increasing over the past decade and previous evidence have indicated the significant relationship between disturbances in hormone levels and the risk of lung cancer. Therefore, we hypothesized female hormone-related cancer (FHRC), including the breast, endometrial, cervix, and ovary cancer, patients may experience a higher risk of developing subsequent lung cancer.
2

Tennis, Meredith A., and Peter G. Shields. Gene Environment Interactions in Women With Breast and Secondary Lung Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2005. http://dx.doi.org/10.21236/ada456364.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Tennis, Meredith A., and Peter G. Shields. Gene Environment Interactions in Women with Breast Cancer and Secondary Lung Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2004. http://dx.doi.org/10.21236/ada428946.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Boushey, Carol, Jamy Ard, Lydia Bazzano, Steven Heymsfield, Elizabeth Mayer-Davis, Joan Sabaté, Linda Snetselaar, et al. Dietary Patterns and Breast, Colorectal, Lung, and Prostate Cancer: A Systematic Review. U.S. Department of Agriculture, Food and Nutrition Service, Center for Nutrition Policy and Promotion, Nutrition Evidence Systematic Review, July 2020. http://dx.doi.org/10.52570/nesr.dgac2020.sr0104.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Battaglia, Tracy, Christine Gunn, Sharon Bak, JoHanna Flacks, Kerrie Nelson, Na Wang, Naomi Ko, and Samantha Morton. Reducing Legal Barriers to Help Patients Receive Treatment for Breast and Lung Cancer—The Project SUPPORT Study. Patient-Centered Outcomes Research Institute (PCORI), July 2020. http://dx.doi.org/10.25302/07.2020.ad.13046272.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Rankin, Nicole, Deborah McGregor, Candice Donnelly, Bethany Van Dort, Richard De Abreu Lourenco, Anne Cust, and Emily Stone. Lung cancer screening using low-dose computed tomography for high risk populations: Investigating effectiveness and screening program implementation considerations: An Evidence Check rapid review brokered by the Sax Institute (www.saxinstitute.org.au) for the Cancer Institute NSW. The Sax Institute, October 2019. http://dx.doi.org/10.57022/clzt5093.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Background Lung cancer is the number one cause of cancer death worldwide.(1) It is the fifth most commonly diagnosed cancer in Australia (12,741 cases diagnosed in 2018) and the leading cause of cancer death.(2) The number of years of potential life lost to lung cancer in Australia is estimated to be 58,450, similar to that of colorectal and breast cancer combined.(3) While tobacco control strategies are most effective for disease prevention in the general population, early detection via low dose computed tomography (LDCT) screening in high-risk populations is a viable option for detecting asymptomatic disease in current (13%) and former (24%) Australian smokers.(4) The purpose of this Evidence Check review is to identify and analyse existing and emerging evidence for LDCT lung cancer screening in high-risk individuals to guide future program and policy planning. Evidence Check questions This review aimed to address the following questions: 1. What is the evidence for the effectiveness of lung cancer screening for higher-risk individuals? 2. What is the evidence of potential harms from lung cancer screening for higher-risk individuals? 3. What are the main components of recent major lung cancer screening programs or trials? 4. What is the cost-effectiveness of lung cancer screening programs (include studies of cost–utility)? Summary of methods The authors searched the peer-reviewed literature across three databases (MEDLINE, PsycINFO and Embase) for existing systematic reviews and original studies published between 1 January 2009 and 8 August 2019. Fifteen systematic reviews (of which 8 were contemporary) and 64 original publications met the inclusion criteria set across the four questions. Key findings Question 1: What is the evidence for the effectiveness of lung cancer screening for higher-risk individuals? There is sufficient evidence from systematic reviews and meta-analyses of combined (pooled) data from screening trials (of high-risk individuals) to indicate that LDCT examination is clinically effective in reducing lung cancer mortality. In 2011, the landmark National Lung Cancer Screening Trial (NLST, a large-scale randomised controlled trial [RCT] conducted in the US) reported a 20% (95% CI 6.8% – 26.7%; P=0.004) relative reduction in mortality among long-term heavy smokers over three rounds of annual screening. High-risk eligibility criteria was defined as people aged 55–74 years with a smoking history of ≥30 pack-years (years in which a smoker has consumed 20-plus cigarettes each day) and, for former smokers, ≥30 pack-years and have quit within the past 15 years.(5) All-cause mortality was reduced by 6.7% (95% CI, 1.2% – 13.6%; P=0.02). Initial data from the second landmark RCT, the NEderlands-Leuvens Longkanker Screenings ONderzoek (known as the NELSON trial), have found an even greater reduction of 26% (95% CI, 9% – 41%) in lung cancer mortality, with full trial results yet to be published.(6, 7) Pooled analyses, including several smaller-scale European LDCT screening trials insufficiently powered in their own right, collectively demonstrate a statistically significant reduction in lung cancer mortality (RR 0.82, 95% CI 0.73–0.91).(8) Despite the reduction in all-cause mortality found in the NLST, pooled analyses of seven trials found no statistically significant difference in all-cause mortality (RR 0.95, 95% CI 0.90–1.00).(8) However, cancer-specific mortality is currently the most relevant outcome in cancer screening trials. These seven trials demonstrated a significantly greater proportion of early stage cancers in LDCT groups compared with controls (RR 2.08, 95% CI 1.43–3.03). Thus, when considering results across mortality outcomes and early stage cancers diagnosed, LDCT screening is considered to be clinically effective. Question 2: What is the evidence of potential harms from lung cancer screening for higher-risk individuals? The harms of LDCT lung cancer screening include false positive tests and the consequences of unnecessary invasive follow-up procedures for conditions that are eventually diagnosed as benign. While LDCT screening leads to an increased frequency of invasive procedures, it does not result in greater mortality soon after an invasive procedure (in trial settings when compared with the control arm).(8) Overdiagnosis, exposure to radiation, psychological distress and an impact on quality of life are other known harms. Systematic review evidence indicates the benefits of LDCT screening are likely to outweigh the harms. The potential harms are likely to be reduced as refinements are made to LDCT screening protocols through: i) the application of risk predication models (e.g. the PLCOm2012), which enable a more accurate selection of the high-risk population through the use of specific criteria (beyond age and smoking history); ii) the use of nodule management algorithms (e.g. Lung-RADS, PanCan), which assist in the diagnostic evaluation of screen-detected nodules and cancers (e.g. more precise volumetric assessment of nodules); and, iii) more judicious selection of patients for invasive procedures. Recent evidence suggests a positive LDCT result may transiently increase psychological distress but does not have long-term adverse effects on psychological distress or health-related quality of life (HRQoL). With regards to smoking cessation, there is no evidence to suggest screening participation invokes a false sense of assurance in smokers, nor a reduction in motivation to quit. The NELSON and Danish trials found no difference in smoking cessation rates between LDCT screening and control groups. Higher net cessation rates, compared with general population, suggest those who participate in screening trials may already be motivated to quit. Question 3: What are the main components of recent major lung cancer screening programs or trials? There are no systematic reviews that capture the main components of recent major lung cancer screening trials and programs. We extracted evidence from original studies and clinical guidance documents and organised this into key groups to form a concise set of components for potential implementation of a national lung cancer screening program in Australia: 1. Identifying the high-risk population: recruitment, eligibility, selection and referral 2. Educating the public, people at high risk and healthcare providers; this includes creating awareness of lung cancer, the benefits and harms of LDCT screening, and shared decision-making 3. Components necessary for health services to deliver a screening program: a. Planning phase: e.g. human resources to coordinate the program, electronic data systems that integrate medical records information and link to an established national registry b. Implementation phase: e.g. human and technological resources required to conduct LDCT examinations, interpretation of reports and communication of results to participants c. Monitoring and evaluation phase: e.g. monitoring outcomes across patients, radiological reporting, compliance with established standards and a quality assurance program 4. Data reporting and research, e.g. audit and feedback to multidisciplinary teams, reporting outcomes to enhance international research into LDCT screening 5. Incorporation of smoking cessation interventions, e.g. specific programs designed for LDCT screening or referral to existing community or hospital-based services that deliver cessation interventions. Most original studies are single-institution evaluations that contain descriptive data about the processes required to establish and implement a high-risk population-based screening program. Across all studies there is a consistent message as to the challenges and complexities of establishing LDCT screening programs to attract people at high risk who will receive the greatest benefits from participation. With regards to smoking cessation, evidence from one systematic review indicates the optimal strategy for incorporating smoking cessation interventions into a LDCT screening program is unclear. There is widespread agreement that LDCT screening attendance presents a ‘teachable moment’ for cessation advice, especially among those people who receive a positive scan result. Smoking cessation is an area of significant research investment; for instance, eight US-based clinical trials are now underway that aim to address how best to design and deliver cessation programs within large-scale LDCT screening programs.(9) Question 4: What is the cost-effectiveness of lung cancer screening programs (include studies of cost–utility)? Assessing the value or cost-effectiveness of LDCT screening involves a complex interplay of factors including data on effectiveness and costs, and institutional context. A key input is data about the effectiveness of potential and current screening programs with respect to case detection, and the likely outcomes of treating those cases sooner (in the presence of LDCT screening) as opposed to later (in the absence of LDCT screening). Evidence about the cost-effectiveness of LDCT screening programs has been summarised in two systematic reviews. We identified a further 13 studies—five modelling studies, one discrete choice experiment and seven articles—that used a variety of methods to assess cost-effectiveness. Three modelling studies indicated LDCT screening was cost-effective in the settings of the US and Europe. Two studies—one from Australia and one from New Zealand—reported LDCT screening would not be cost-effective using NLST-like protocols. We anticipate that, following the full publication of the NELSON trial, cost-effectiveness studies will likely be updated with new data that reduce uncertainty about factors that influence modelling outcomes, including the findings of indeterminate nodules. Gaps in the evidence There is a large and accessible body of evidence as to the effectiveness (Q1) and harms (Q2) of LDCT screening for lung cancer. Nevertheless, there are significant gaps in the evidence about the program components that are required to implement an effective LDCT screening program (Q3). Questions about LDCT screening acceptability and feasibility were not explicitly included in the scope. However, as the evidence is based primarily on US programs and UK pilot studies, the relevance to the local setting requires careful consideration. The Queensland Lung Cancer Screening Study provides feasibility data about clinical aspects of LDCT screening but little about program design. The International Lung Screening Trial is still in the recruitment phase and findings are not yet available for inclusion in this Evidence Check. The Australian Population Based Screening Framework was developed to “inform decision-makers on the key issues to be considered when assessing potential screening programs in Australia”.(10) As the Framework is specific to population-based, rather than high-risk, screening programs, there is a lack of clarity about transferability of criteria. However, the Framework criteria do stipulate that a screening program must be acceptable to “important subgroups such as target participants who are from culturally and linguistically diverse backgrounds, Aboriginal and Torres Strait Islander people, people from disadvantaged groups and people with a disability”.(10) An extensive search of the literature highlighted that there is very little information about the acceptability of LDCT screening to these population groups in Australia. Yet they are part of the high-risk population.(10) There are also considerable gaps in the evidence about the cost-effectiveness of LDCT screening in different settings, including Australia. The evidence base in this area is rapidly evolving and is likely to include new data from the NELSON trial and incorporate data about the costs of targeted- and immuno-therapies as these treatments become more widely available in Australia.
7

Deng, Chun, Zhenyu Zhang, Zhi Guo, Hengduo Qi, Yang Liu, Haimin Xiao, and Xiaojun Li. Assessment of intraoperative use of indocyanine green fluorescence imaging on the number of lymph node dissection during minimally invasive gastrectomy: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0062.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Review question / Objective: Whether is indocyanine green fluorescence imaging-guided lymphadenectomy feasible to improve the number of lymph node dissections during radical gastrectomy in patients with gastric cancer undergoing curative resection? Condition being studied: Gastric cancer was the sixth most common malignant tumor and the fourth leading cause of cancer-related death in the world. Radical lymphadenectomy was a standard procedure in radical gastrectomy for gastric cancer. The retrieval of more lymph nodes was beneficial for improving the accuracy of tumor staging and the long-term survival of patients with gastric cancer. Indocyanine green(ICG) near-infrared fluorescent imaging has been found to provide surgeons with effective visualization of the lymphatic anatomy. As a new surgical navigation technique, ICG near-infrared fluorescent imaging was a hot spot and had already demonstrated promising results in the localization of lymph nodes during surgery in patients with breast cancer, non–small cell lung cancer, and gastric cancer. In addition, ICG had increasingly been reported in the localization of tumor, lymph node dissection, and the evaluation of anastomotic blood supply during radical gastrectomy for gastric cancer. However, it remained unclear whether ICG fluorescence imaging would assist surgeons in performing safe and sufficient lymphadenectomy.
8

Guo, Lijuan, Xiaoyi Lin, Xin Lin, Yulei Wang, Jiali Lin, Yi Zhang, Xiangqing Chen, Miao Chen, Guochun Zhang, and Yifang Zhang. Risk of Interstitial Lung Disease With Use of Programmed Cell Death 1 Inhibitors versus Programmed Cell Death Ligand 1 Inhibitors In Breast Cancer: A meta-analysis and Cases description. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2023. http://dx.doi.org/10.37766/inplasy2023.6.0007.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Garsa, Adam, Julie K. Jang, Sangita Baxi, Christine Chen, Olamigoke Akinniranye, Owen Hall, Jody Larkin, Aneesa Motala, Sydne Newberry, and Susanne Hempel. Radiation Therapy for Brain Metasases. Agency for Healthcare Research and Quality (AHRQ), June 2021. http://dx.doi.org/10.23970/ahrqepccer242.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Анотація:
Objective. This evidence report synthesizes the available evidence on radiation therapy for brain metastases. Data sources. We searched PubMed®, Embase®, Web of Science, Scopus, CINAHL®, clinicaltrials.gov, and published guidelines in July 2020; assessed independently submitted data; consulted with experts; and contacted authors. Review methods. The protocol was informed by Key Informants. The systematic review was supported by a Technical Expert Panel and is registered in PROSPERO (CRD42020168260). Two reviewers independently screened citations; data were abstracted by one reviewer and checked by an experienced reviewer. We included randomized controlled trials (RCTs) and large observational studies (for safety assessments), evaluating whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) alone or in combination, as initial or postoperative treatment, with or without systemic therapy for adults with brain metastases due to non-small cell lung cancer, breast cancer, or melanoma. Results. In total, 97 studies, reported in 190 publications, were identified, but the number of analyses was limited due to different intervention and comparator combinations as well as insufficient reporting of outcome data. Risk of bias varied; 25 trials were terminated early, predominantly due to poor accrual. Most studies evaluated WBRT, alone or in combination with SRS, as initial treatment; 10 RCTs reported on post-surgical interventions. The combination treatment SRS plus WBRT compared to SRS alone or WBRT alone showed no statistically significant difference in overall survival (hazard ratio [HR], 1.09; confidence interval [CI], 0.69 to 1.73; 4 RCTs; low strength of evidence [SoE]) or death due to brain metastases (relative risk [RR], 0.93; CI, 0.48 to 1.81; 3 RCTs; low SoE). Radiation therapy after surgery did not improve overall survival compared with surgery alone (HR, 0.98; CI, 0.76 to 1.26; 5 RCTs; moderate SoE). Data for quality of life, functional status, and cognitive effects were insufficient to determine effects of WBRT, SRS, or post-surgical interventions. We did not find systematic differences across interventions in serious adverse events radiation necrosis, fatigue, or seizures (all low or moderate SoE). WBRT plus systemic therapy (RR, 1.44; CI, 1.03 to 2.00; 14 studies; moderate SoE) was associated with increased risks for vomiting compared to WBRT alone. Conclusion. Despite the substantial research literature on radiation therapy, comparative effectiveness information is limited. There is a need for more data on patient-relevant outcomes such as quality of life, functional status, and cognitive effects.
10

Dave, Dhaval, Daniel Dench, Donald Kenkel, Alan Mathios, and Hua Wang. News that Takes Your Breath Away: Risk Perceptions During an Outbreak of Vaping-related Lung Injuries. Cambridge, MA: National Bureau of Economic Research, April 2020. http://dx.doi.org/10.3386/w26977.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

До бібліографії